Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Affluent Medical SA ( (FR:AFME) ) has shared an announcement.
Affluent Medical has announced key leadership appointments to accelerate its progress towards market access for its advanced medical devices. Dr. Howard C. Herrmann and Pr. Nicolas Barry Delongchamps have been appointed as Chief Medical Officers for the Structural Heart and Urology platforms, respectively, while Federica Azzimonti joins as Director of Clinical Operations. These strategic hires aim to enhance clinical expertise and operational capabilities, supporting the company’s growth and transition towards commercialization of its innovative products. The appointments are expected to strengthen Affluent Medical’s position in the medical technology industry and drive innovation in the treatment of structural heart diseases and urinary incontinence.
More about Affluent Medical SA
Affluent Medical is a French clinical-stage medical technology company specializing in the development and industrialization of innovative implantable medical devices. The company focuses on treating structural heart diseases and urinary incontinence, aiming to become a global leader in these areas. Affluent Medical’s products are minimally invasive, adjustable, and biomimetic, designed to restore essential physiological functions, with all candidate products currently undergoing clinical studies.
YTD Price Performance: 7.14%
Average Trading Volume: 500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €53.87M
For a thorough assessment of AFME stock, go to TipRanks’ Stock Analysis page.